PROCEPT BioRobotics Corp. (PRCT)

PROCEPT BioRobotics' stock has experienced several events in the past six months. In November 2025, the company reported strong third-quarter results and increased guidance, leading to "Buy" ratings from analysts. However, the stock experienced a pullback due to a fourth-quarter revenue shortfall in February 2026, despite an improved handpiece average selling price and updated 2026 revenue guidance. Positive catalysts included the international launch of the HYDROS Robotic System in March 2026 and the European Association of Urology's (EAU) upgraded recommendation for Aquablation therapy. In April 2026, first-quarter results showed a revenue increase, but the diluted loss per share widened, and full-year guidance was reaffirmed, causing investor caution. Insider trading activity and institutional investor adjustments were also noted.

Information explicitly detailing demand seasonality for PROCEPT BioRobotics' products and services is not available. However, the company's focus on treating benign prostatic hyperplasia (BPH) suggests a consistent underlying demand. The company's strategy to convert revenue mix from system sales to more stable handpiece replacements also indicates a move towards more recurring and potentially less seasonal revenue streams.

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urological solutions. They develop, manufacture, and sell advanced, image-guided, surgical robotic systems, including the AquaBeam and HYDROS Robotic Systems, which deliver Aquablation therapy for targeted prostate tissue removal. The initial focus is on treating benign prostatic hyperplasia (BPH), and they are evaluating Aquablation therapy for localized prostate cancer.

PROCEPT BioRobotics generates most of its revenue from the United States but also has an international presence. In March 2026, they announced the international expansion of its HYDROS Robotic System, launching first in the UK, with further international expansion planned for 2026. As of March 31, 2026, the global installed base of robotic systems reached 971, with 765 in the U.S.

PROCEPT BioRobotics' brand reputation has been positively impacted by the European Association of Urology's strong recommendation for Aquablation therapy for BPH treatment in March 2026. The company has also been expanding the international rollout of its HYDROS Robotic System. However, there have been mentions of securities fraud investigations into PROCEPT BioRobotics Corporation.

PROCEPT BioRobotics has significant institutional ownership, with 270 institutional owners holding 57,278,054 shares as of May 5, 2026. Major institutional shareholders include Vanguard Group Inc, Fmr Llc, and BlackRock, Inc. Cpmg Inc is the largest individual shareholder. Recent insider trading activity includes purchases by Antal Rohit Desai and sales by Alaleh Nouri and Kevin Waters.